Literature DB >> 21655705

Mechanisms of RON-mediated epithelial-mesenchymal transition in MDCK cells through the MAPK pathway.

Xu Xiangming1, Qian Yun, Zhang Guoliang, Lin Jianjiang, Teng Lisong.   

Abstract

The epithelial-mesenchymal transition (EMT) is involved in neoplastic metastasis, and the RON protein may be involved. In the present study, we determined the role and the mechanisms of action of RON in EMT in Madin-Darby canine kidney (MDCK) cells by Western blot and cell migration analysis. Activation of RON by macrophage stimulating protein (MSP) results in cell migration and initiates changes in the morphology of RON-cDNA-transfected MDCK cells. The absence of E-cadherin, the presence of vimentin and an increase in Snail were observed in RE7 cells, which were derived from MDCK cells transfected with wt-RON, compared with MDCK cells. Stimulation of RE7 cells with MSP resulted in increased migration (about 69% of the wounded areas were covered) as well as increased activation of extracellular signal-regulated kinase 1/2 (Erk1/2) and glycogen synthase kinase-3β (GSK-3β; the percent of the activation ratio was 143.6/599.8% and 512.4%, respectively), which could be inhibited with an individual chemical inhibitor PD98059 (50 μM) specific to MAPK/ERK kinase (the percent inhibition was 98.9 and 81.2%, respectively). Thus, the results indicated that RON protein could mediate EMT in MDCK cells via the Erk1/2 pathway. Furthermore, GSK-3β regulates the function of Snail in controlling EMT by this pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21655705     DOI: 10.1590/s0100-879x2011007500070

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  8 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

Review 2.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

3.  Role of fucosyltransferase IV in epithelial-mesenchymal transition in breast cancer cells.

Authors:  X Yang; S Liu; Q Yan
Journal:  Cell Death Dis       Date:  2013-07-25       Impact factor: 8.469

4.  Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines.

Authors:  Dong-Hui Zhou; Chao Li; Li-Na Yang
Journal:  Cancer Cell Int       Date:  2015-02-04       Impact factor: 5.722

5.  RON Receptor Tyrosine Kinase Regulates Epithelial Mesenchymal Transition and the Expression of Pro-Fibrotic Markers via Src/Smad Signaling in HK-2 and NRK49F Cells.

Authors:  Jung Sun Park; Hoon-In Choi; Dong-Hyun Kim; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Soo Wan Kim
Journal:  Int J Mol Sci       Date:  2019-11-04       Impact factor: 5.923

6.  Trefoil Factor-3 (TFF3) Stimulates De Novo Angiogenesis in Mammary Carcinoma both Directly and Indirectly via IL-8/CXCR2.

Authors:  Wai-Hoe Lau; Vijay Pandey; Xiangjun Kong; Xiao-Nan Wang; ZhengSheng Wu; Tao Zhu; Peter E Lobie
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

7.  High-throughput mRNA and miRNA profiling of epithelial-mesenchymal transition in MDCK cells.

Authors:  Priyank Shukla; Claus Vogl; Barbara Wallner; Doris Rigler; Mathias Müller; Sabine Macho-Maschler
Journal:  BMC Genomics       Date:  2015-11-16       Impact factor: 3.969

8.  mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential.

Authors:  Najme Faham; Ling Zhao; Alana L Welm
Journal:  NPJ Breast Cancer       Date:  2018-11-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.